Table 1.
Patients’, CVC, and CRBSI characteristics of the entire cohort (n = 5,075)
| Parameter | Men (n = 3,012) | Women (n = 2,063) | p value |
|---|---|---|---|
| Patients | |||
| Median age (95% CI), years | 59 (58–59) | 60 (59–60) | 0.18a |
| Underlying cancer, n (%) | <0.001b | ||
| Acute myeloid leukemia | 1,052 (34.9) | 857 (41.5) | |
| Multiple myeloma | 694 (23.0) | 441 (21.4) | |
| Non-Hodgkin lymphoma | 604 (20.1) | 372 (18.0) | |
| Acute lymphoblastic leukemia | 227 (7.5) | 159 (7.7) | |
| Hodgkin lymphoma | 69 (2.3) | 68 (3.3) | |
| Myeloproliferative neoplasm | 77 (2.6) | 22 (1.1) | |
| Myelodysplastic neoplasm | 47 (1.6) | 40 (1.9) | |
| Germ-cell tumor | 78 (2.6) | 0 | |
| Sarcoma | 66 (2.2) | 47 (2.3) | |
| Carcinoma | 98 (3.3) | 57 (2.8) | |
| Neutropenia at CVC insertion, n (%) | 488 (16.2) | 337 (16.3) | 0.91c |
| Neutropenia at CRBSI diagnosis, n/N (%) | |||
| dCRBSI | 128/157 (81.5) | 67/88 (76.1) | 0.33c |
| dpCRBSI | 256/298 (85.9) | 110/138 (79.7) | 0.12c |
| Neutropenia at CVC removal, n (%) | 924 (30.7) | 601 (29.1) | 0.25c |
| CVCs | |||
| Anatomic site, n (%) | 0.02c | ||
| Internal jugular vein | 2,882 (95.7) | 1,945 (94.3) | |
| Subclavian vein | 130 (4.3%) | 118 (5.7%) | |
| CHG-coated CVC dressing, n (%) | 1,099 (36.5) | 712 (34.5) | 0.15c |
| Antimicrobial coated CVC, n (%) | 365 (12.1) | 235 (11.4) | 0.45c |
| Complicated CVC insertion, n (%) | 305 (10.1) | 237 (11.5) | 0.13c |
| CVC in situ time, days | |||
| Median (95% CI) | 14 (13–14) | 14 (14–15) | 0.23a |
| Range | 1–89 | 1–93 | |
| CRBSI | |||
| CRBSI rate, n (%) | |||
| dCRBSI | 157 (5.2) | 88 (4.3) | 0.13c |
| dpCRBSI | 298 (9.9) | 138 (6.7) | <0.001c |
| CRBSI incidence, x/1,000 CVC days | |||
| dCRBSI | 3.5 | 2.7 | 0.07d |
| dpCRBSI | 6.6 | 4.3 | <0.001d |
| Time to CRBSI onset, days | |||
| dCRBSI | |||
| Median (95% CI) | 13 (12–15) | 13 (11–16) | 0.89a |
| Range | 3–67 | 1–75 | |
| dpCRBSI | |||
| Median (95% CI) | 12 (12–13) | 13 (12–15) | 0.68a |
| Range | 1–67 | 1–75 | |
| Causative CRBSI pathogens, n/N (%) | |||
| dCRBSI | 0.72b | ||
| CoNS | 111/157 (70.7) | 57/88 (64.8) | |
| Other Gram-positive bacteria | 15/157 (9.6) | 8/88 (9.1) | |
| Enterobacteriaceae | 10/157 (6.4) | 11/88 (12.5) | |
| Other Gram-negative bacteria | 9/157 (5.7) | 5/88 (5.7) | |
| Candida spp. | 6/157 (3.8) | 4/88 (4.5) | |
| Polymicrobial | 6/157 (3.8) | 3/88 (3.4) | |
| dpCRBSI | 0.16b | ||
| CoNS | 219/298 (73.5) | 91/138 (65.9) | |
| Other Gram-positive bacteria | 33/298 (11.1) | 17/138 (12.3) | |
| Enterobacteriaceae | 12/298 (4.0) | 13/138 (9.4) | |
| Other Gram-negative bacteria | 11/298 (3.7) | 5/138 (3.6) | |
| Candida spp. | 7/298 (2.3) | 7/138 (5.1) | |
| Polymicrobial | 16/298 (5.4) | 5/138 (3.6) | |
CVC, central venous catheter; CHG, chlorhexidine gluconate gel pad; CRBSI, CVC-related bloodstream infection; dCRBSI, definite CRBSI; dpCRBSI, definite plus probable CRBSI; 95% CI, 95% confidence interval.
aMann-Whitney U test.
bPearson χ2 test.
cFisher exact test.
dMid-P exact test.